FDA approves J&J's Tremfya for psoriasis

FDA approved Tremfya guselkumab (CNTO 1959) from Johnson & Johnson (NYSE:JNJ) to treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Spokesperson Brian Kenney told BioCentury that J&J expects to launch Tremfya within 2 weeks at an annual wholesale acquisition cost (WAC) of $58,100.

Tremfya is a human HuCAL mAb targeting the p19 subunit of IL-23...